Physician profile
Roberto A Beaton
NPI 1669550885
$1,263.78
in general payments reported to CMS, 2019-2025
19 companies · $72.84 in 2025
The $72.84 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $171 · 2021: $43.45 · 2022: $77.55 · 2023: $152 · 2024: $239 · 2025: $72.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $275.58 | 2019-2025 | Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $151.03 | 2019-2020 | |
| Astellas Pharma US INC | $146.59 | 2019-2021 | |
| Amgen INC. | $128.25 | 2019-2024 | Prolia, Evenity |
| Novo Nordisk INC | $126.93 | 2020-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $111.68 | 2019-2024 | |
| Lilly USA, LLC | $59.17 | 2022 | |
| Glaxosmithkline, LLC. | $44.12 | 2023-2024 | Trelegy Ellipta |
| Ironwood Pharmaceuticals, INC | $33.95 | 2023 | Linzess |
| Pfizer INC. | $28.55 | 2023-2024 | |
| Radius Health, INC. | $23.95 | 2020 | |
| Amarin Pharma, INC. | $19.99 | 2019 | |
| Sun Pharmaceutical Industries INC. | $19.28 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.38 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.43 | 2023 | Jardiance |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $16.11 | 2024 | |
| Janssen Pharmaceuticals, INC | $15.89 | 2020 | |
| Vertiflex, INC. | $15.76 | 2019 | |
| Merck Sharp & Dohme LLC | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Beaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.